{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:26:35Z","timestamp":1785273995219,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Nilsson-Ehle foundation","award":["29211"],"award-info":[{"award-number":["29211"]}]},{"name":"the Swedish Childhood Cancer foundation","award":["NBCNSPDHEL10\/021"],"award-info":[{"award-number":["NBCNSPDHEL10\/021"]}]},{"name":"the Swedish Childhood Cancer foundation","award":["2016-147"],"award-info":[{"award-number":["2016-147"]}]},{"DOI":"10.13039\/501100001862","name":"the Swedish research council","doi-asserted-by":"crossref","award":["2014-3031"],"award-info":[{"award-number":["2014-3031"]}],"id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012538","name":"the Swedish Cancer foundation","doi-asserted-by":"crossref","award":["18-1711"],"award-info":[{"award-number":["18-1711"]}],"id":[{"id":"10.13039\/100012538","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Swedish state under the LUA\/ALF agreement","award":["ALFGBG-447171"],"award-info":[{"award-number":["ALFGBG-447171"]}]},{"name":"the Swedish Foundation for Strategic Research","award":["RB13-0204"],"award-info":[{"award-number":["RB13-0204"]}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In neuroblastoma, <jats:italic>MYCN<\/jats:italic> amplification and 11q-deletion are important, although incomplete, markers of high-risk disease. It is therefore relevant to characterize additional alterations that can function as prognostic and\/or predictive markers. Using SNP-microarrays, a group of neuroblastoma patients showing amplification of one or multiple 12q loci was identified. Two loci containing <jats:italic>CDK4<\/jats:italic> and <jats:italic>MDM2<\/jats:italic> were commonly co-amplified, although amplification of either locus in the absence of the other was observed. Pharmacological inhibition of CDK4\/6 with ribociclib or abemaciclib decreased proliferation in a broad set of neuroblastoma cell lines, including <jats:italic>CDK4\/MDM2<\/jats:italic>-amplified, whereas MDM2 inhibition by Nutlin-3a was only effective in p53<jats:sup>wild-type<\/jats:sup> cells. Combined CDK4\/MDM2 targeting had an additive effect in p53<jats:sup>wild-type<\/jats:sup> cell lines, while no or negative additive effect was observed in p53<jats:sup>mutated<\/jats:sup> cells. Most 12q-amplified primary tumors were of abdominal origin, including those of intrarenal origin initially suspected of being Wilms\u2019 tumor. An atypical metastatic pattern was also observed with low degree of bone marrow involvement, favoring other sites such as the lungs. Here we present detailed biological data of an aggressive neuroblastoma subgroup hallmarked by 12q amplification and atypical clinical presentation for which our in vitro studies indicate that CDK4 and\/or MDM2 inhibition also could be beneficial.<\/jats:p>","DOI":"10.1038\/s41598-022-16455-1","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T14:04:28Z","timestamp":1658325868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup"],"prefix":"10.1038","volume":"12","author":[{"given":"Angela","family":"Martinez-Monleon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kryh \u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Gaarder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Berbegall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Javanmardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Djos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ussowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Taschner-Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Ambros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"\u00d8ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Sandstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ladenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Noguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Ambros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Gordon Murkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustaf","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Kogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Fransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Martinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"16455_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00043426-199905000-00005","volume":"21","author":"SG DuBois","year":"1999","unstructured":"DuBois, S. G. et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J. Pediatr. Hematol. Oncol. 21, 181\u2013189 (1999).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"16455_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/pbc.24713","volume":"61","author":"D Valteau-Couanet","year":"2014","unstructured":"Valteau-Couanet, D. et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr. Blood Cancer 61, 977\u2013981. https:\/\/doi.org\/10.1002\/pbc.24713 (2014).","journal-title":"Pediatr. Blood Cancer"},{"key":"16455_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","volume":"9","author":"AD Pearson","year":"2008","unstructured":"Pearson, A. D. et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 9, 247\u2013256. https:\/\/doi.org\/10.1016\/S1470-2045(08)70069-X (2008).","journal-title":"Lancet Oncol."},{"key":"16455_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2529","volume":"45","author":"TJ Pugh","year":"2013","unstructured":"Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279\u2013284. https:\/\/doi.org\/10.1038\/ng.2529 (2013).","journal-title":"Nat. Genet."},{"key":"16455_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ccell.2014.09.014","volume":"26","author":"GK Pandey","year":"2014","unstructured":"Pandey, G. K. et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 26, 722\u2013737. https:\/\/doi.org\/10.1016\/j.ccell.2014.09.014 (2014).","journal-title":"Cancer Cell"},{"key":"16455_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nature10910","volume":"483","author":"JJ Molenaar","year":"2012","unstructured":"Molenaar, J. J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589\u2013593. https:\/\/doi.org\/10.1038\/nature10910 (2012).","journal-title":"Nature"},{"key":"16455_CR7","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1073\/pnas.0910684107","volume":"107","author":"H Caren","year":"2010","unstructured":"Caren, H. et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc. Natl. Acad. Sci. U. S. A. 107, 4323\u20134328. https:\/\/doi.org\/10.1073\/pnas.0910684107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16455_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/mpo.2950240402","volume":"24","author":"H Caron","year":"1995","unstructured":"Caron, H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Pediatr. Oncol. 24, 215\u2013221 (1995).","journal-title":"Med. Pediatr. Oncol."},{"key":"16455_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/15384047.2019.1704122","volume":"21","author":"M Ognibene","year":"2020","unstructured":"Ognibene, M., Morini, M., Garaventa, A., Podesta, M. & Pezzolo, A. Identification of a minimal region of loss on chromosome 6q27 associated with poor survival of high-risk neuroblastoma patients. Cancer Biol. Ther. 21, 391\u2013399. https:\/\/doi.org\/10.1080\/15384047.2019.1704122 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"16455_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/jnci\/djy022","volume":"110","author":"P Depuydt","year":"2018","unstructured":"Depuydt, P. et al. Genomic amplifications and distal 6q loss: Novel markers for poor survival in high-risk neuroblastoma patients. J. Natl. Cancer Inst. 110, 1084\u20131093. https:\/\/doi.org\/10.1093\/jnci\/djy022 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"16455_CR11","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-16-2082","volume":"23","author":"MR Abbasi","year":"2017","unstructured":"Abbasi, M. R. et al. Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone. Clin. Cancer Res. 23, 4224\u20134232. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2082 (2017).","journal-title":"Clin. Cancer Res."},{"key":"16455_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aat6768","volume":"362","author":"S Ackermann","year":"2018","unstructured":"Ackermann, S. et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science 362, 1165\u20131170. https:\/\/doi.org\/10.1126\/science.aat6768 (2018).","journal-title":"Science"},{"key":"16455_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/ng.3333","volume":"47","author":"TF Eleveld","year":"2015","unstructured":"Eleveld, T. F. et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat. Genet. 47, 864\u2013871. https:\/\/doi.org\/10.1038\/ng.3333 (2015).","journal-title":"Nat. Genet."},{"key":"16455_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1126\/science.6719137","volume":"224","author":"GM Brodeur","year":"1984","unstructured":"Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121\u20131124. https:\/\/doi.org\/10.1126\/science.6719137 (1984).","journal-title":"Science"},{"key":"16455_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJM198510313131802","volume":"313","author":"RC Seeger","year":"1985","unstructured":"Seeger, R. C. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111\u20131116. https:\/\/doi.org\/10.1056\/NEJM198510313131802 (1985).","journal-title":"N. Engl. J. Med."},{"key":"16455_CR16","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-09-2660","volume":"16","author":"S De Brouwer","year":"2010","unstructured":"De Brouwer, S. et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353\u20134362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2660 (2010).","journal-title":"Clin. Cancer Res."},{"key":"16455_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101990","volume":"9","author":"A Guimier","year":"2014","unstructured":"Guimier, A. et al. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN. PLoS\u00a0One 9, e101990. https:\/\/doi.org\/10.1371\/journal.pone.0101990 (2014).","journal-title":"PLoS\u00a0One"},{"key":"16455_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/1471-2164-9-353","volume":"9","author":"H Caren","year":"2008","unstructured":"Caren, H. et al. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene. BMC Genom. 9, 353. https:\/\/doi.org\/10.1186\/1471-2164-9-353 (2008).","journal-title":"BMC Genom."},{"key":"16455_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/gcc.10166","volume":"36","author":"JJ Molenaar","year":"2003","unstructured":"Molenaar, J. J., van Sluis, P., Boon, K., Versteeg, R. & Caron, H. N. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 36, 242\u2013249. https:\/\/doi.org\/10.1002\/gcc.10166 (2003).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/gcc.20477","volume":"46","author":"YP Mosse","year":"2007","unstructured":"Mosse, Y. P. et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46, 936\u2013949. https:\/\/doi.org\/10.1002\/gcc.20477 (2007).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/gcc.22827","volume":"59","author":"L Amoroso","year":"2020","unstructured":"Amoroso, L. et al. Genomic coamplification of CDK4\/MDM2\/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosomes Cancer 59, 277\u2013285. https:\/\/doi.org\/10.1002\/gcc.22827 (2020).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2014.00202","volume":"4","author":"IM Ambros","year":"2014","unstructured":"Ambros, I. M., Brunner, C., Abbasi, R., Frech, C. & Ambros, P. F. Ultra-high density SNParray in neuroblastoma molecular diagnostics. Front. Oncol. 4, 202. https:\/\/doi.org\/10.3389\/fonc.2014.00202 (2014).","journal-title":"Front. Oncol."},{"key":"16455_CR23","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1002\/ijc.23380","volume":"122","author":"A Italiano","year":"2008","unstructured":"Italiano, A. et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int. J. Cancer 122, 2233\u20132241. https:\/\/doi.org\/10.1002\/ijc.23380 (2008).","journal-title":"Int. J. Cancer"},{"key":"16455_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/path.1495","volume":"202","author":"I Hostein","year":"2004","unstructured":"Hostein, I. et al. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: A potential tool for the diagnosis of atypical lipomatous tumours\/well-differentiated liposarcomas. J. Pathol. 202, 95\u2013102. https:\/\/doi.org\/10.1002\/path.1495 (2004).","journal-title":"J. Pathol."},{"key":"16455_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/gcc.20761","volume":"49","author":"S Mejia-Guerrero","year":"2010","unstructured":"Mejia-Guerrero, S. et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49, 518\u2013525. https:\/\/doi.org\/10.1002\/gcc.20761 (2010).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/gcc.1219","volume":"33","author":"D Gisselsson","year":"2002","unstructured":"Gisselsson, D. et al. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer 33, 133\u2013140 (2002).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cancergen.2017.09.005","volume":"218\u2013219","author":"RW Ricciotti","year":"2017","unstructured":"Ricciotti, R. W. et al. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. Cancer Genet. 218\u2013219, 69\u201380. https:\/\/doi.org\/10.1016\/j.cancergen.2017.09.005 (2017).","journal-title":"Cancer Genet."},{"key":"16455_CR28","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/sj.onc.1205304","volume":"21","author":"R Simon","year":"2002","unstructured":"Simon, R. et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21, 2476\u20132483. https:\/\/doi.org\/10.1038\/sj.onc.1205304 (2002).","journal-title":"Oncogene"},{"key":"16455_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0002-9440(10)65257-1","volume":"154","author":"HX An","year":"1999","unstructured":"An, H. X., Beckmann, M. W., Reifenberger, G., Bender, H. G. & Niederacher, D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154, 113\u2013118. https:\/\/doi.org\/10.1016\/S0002-9440(10)65257-1 (1999).","journal-title":"Am. J. Pathol."},{"key":"16455_CR30","first-page":"5141","volume":"56","author":"G Reifenberger","year":"1996","unstructured":"Reifenberger, G. et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4\/SAS and MDM2 as independent amplification targets. Can. Res. 56, 5141\u20135145 (1996).","journal-title":"Can. Res."},{"key":"16455_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/gcc.20122","volume":"42","author":"H Wikman","year":"2005","unstructured":"Wikman, H. et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3\u2013q14.1 in lung cancer. Genes Chromosomes Cancer 42, 193\u2013199. https:\/\/doi.org\/10.1002\/gcc.20122 (2005).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/gcc.20310","volume":"45","author":"V Muthusamy","year":"2006","unstructured":"Muthusamy, V. et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45, 447\u2013454. https:\/\/doi.org\/10.1002\/gcc.20310 (2006).","journal-title":"Genes Chromosomes Cancer"},{"key":"16455_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","volume":"18","author":"R Ladenstein","year":"2017","unstructured":"Ladenstein, R. et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): An international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 18, 500\u2013514. https:\/\/doi.org\/10.1016\/S1470-2045(17)30070-0 (2017).","journal-title":"Lancet Oncol."},{"key":"16455_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/pbc.21684","volume":"51","author":"SG Dubois","year":"2008","unstructured":"Dubois, S. G. et al. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr. Blood Cancer 51, 589\u2013592. https:\/\/doi.org\/10.1002\/pbc.21684 (2008).","journal-title":"Pediatr. Blood Cancer"},{"key":"16455_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23091","author":"CB Bui","year":"2019","unstructured":"Bui, C. B. et al. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Mol. Carcinog. https:\/\/doi.org\/10.1002\/mc.23091 (2019).","journal-title":"Mol. Carcinog."},{"key":"16455_CR36","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.bbrc.2007.01.057","volume":"354","author":"Y Nakamura","year":"2007","unstructured":"Nakamura, Y. et al. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem. Biophys. Res. Commun. 354, 892\u2013898. https:\/\/doi.org\/10.1016\/j.bbrc.2007.01.057 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"16455_CR37","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1093\/nar\/gkl619","volume":"34","author":"D Goldschneider","year":"2006","unstructured":"Goldschneider, D. et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34, 5603\u20135612. https:\/\/doi.org\/10.1093\/nar\/gkl619 (2006).","journal-title":"Nucleic Acids Res."},{"key":"16455_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-019-1066-6","volume":"38","author":"V Mlakar","year":"2019","unstructured":"Mlakar, V. et al. PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. J. Exp. Clin. Cancer Res. 38, 69. https:\/\/doi.org\/10.1186\/s13046-019-1066-6 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"16455_CR39","doi-asserted-by":"publisher","first-page":"46203","DOI":"10.18632\/oncotarget.10073","volume":"7","author":"CJ Drummond","year":"2016","unstructured":"Drummond, C. J. et al. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget 7, 46203\u201346218. https:\/\/doi.org\/10.18632\/oncotarget.10073 (2016).","journal-title":"Oncotarget"},{"key":"16455_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1515\/bmc-2013-0026","volume":"4","author":"A Matsui","year":"2013","unstructured":"Matsui, A., Ihara, T., Suda, H., Mikami, H. & Semba, K. Gene amplification: Mechanisms and involvement in cancer. Biomol. Concepts 4, 567\u2013582. https:\/\/doi.org\/10.1515\/bmc-2013-0026 (2013).","journal-title":"Biomol. Concepts"},{"key":"16455_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/bj20081834","volume":"416","author":"H Caren","year":"2008","unstructured":"Caren, H., Abel, F., Kogner, P. & Martinsson, T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416, 153\u2013159. https:\/\/doi.org\/10.1042\/bj20081834 (2008).","journal-title":"Biochem. J."},{"key":"16455_CR42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/35106065","volume":"1","author":"M Malumbres","year":"2001","unstructured":"Malumbres, M. & Barbacid, M. To cycle or not to cycle: A critical decision in cancer. Nat. Rev. Cancer 1, 222\u2013231. https:\/\/doi.org\/10.1038\/35106065 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"16455_CR43","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41467-021-21247-8","volume":"12","author":"SA Hartlieb","year":"2021","unstructured":"Hartlieb, S. A. et al. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. Nat. Commun. 12, 1269. https:\/\/doi.org\/10.1038\/s41467-021-21247-8 (2021).","journal-title":"Nat. Commun."},{"key":"16455_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3892\/ijo.2016.3349","volume":"48","author":"S Fransson","year":"2016","unstructured":"Fransson, S. et al. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and iin neuroblastoma. Int. J. Oncol. 48, 1103\u20131116. https:\/\/doi.org\/10.3892\/ijo.2016.3349 (2016).","journal-title":"Int. J. Oncol."},{"key":"16455_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S2352-4642(19)30018-5","volume":"3","author":"S Mahamdallie","year":"2019","unstructured":"Mahamdallie, S. et al. Identification of new Wilms tumour predisposition genes: An exome sequencing study. Lancet. Child Adolesc. Health 3, 322\u2013331. https:\/\/doi.org\/10.1016\/S2352-4642(19)30018-5 (2019).","journal-title":"Lancet. Child Adolesc. Health"},{"key":"16455_CR46","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/17460441.2017.1340269","volume":"12","author":"L Moreno","year":"2017","unstructured":"Moreno, L. et al. Accelerating drug development for neuroblastoma\u2014New drug development strategy: An innovative therapies for children with cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin. Drug Discov. 12, 801\u2013811. https:\/\/doi.org\/10.1080\/17460441.2017.1340269 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"16455_CR47","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","volume":"23","author":"B Geoerger","year":"2017","unstructured":"Geoerger, B. et al. A phase I study of the CDK4\/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin. Cancer Res. 23, 2433\u20132441. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2898 (2017).","journal-title":"Clin. Cancer Res."},{"key":"16455_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-017-0482-3","volume":"10","author":"A Laroche-Clary","year":"2017","unstructured":"Laroche-Clary, A. et al. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. J. Hematol. Oncol. 10, 123. https:\/\/doi.org\/10.1186\/s13045-017-0482-3 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"16455_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7171","author":"AE Vilgelm","year":"2019","unstructured":"Vilgelm, A. E. et al. MDM2 antagonists overcome intrinsic resistance to CDK4\/6 inhibition by inducing p21. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav7171 (2019).","journal-title":"Sci. Transl. Med."},{"key":"16455_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13058-020-01318-2","volume":"22","author":"N Portman","year":"2020","unstructured":"Portman, N. et al. MDM2 inhibition in combination with endocrine therapy and CDK4\/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Res. 22, 87. https:\/\/doi.org\/10.1186\/s13058-020-01318-2 (2020).","journal-title":"Breast Cancer Res."},{"key":"16455_CR51","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-018-0968-0","volume":"9","author":"A Sriraman","year":"2018","unstructured":"Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A. & Dobbelstein, M. CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death Dis. 9, 918. https:\/\/doi.org\/10.1038\/s41419-018-0968-0 (2018).","journal-title":"Cell Death Dis."},{"key":"16455_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.10.009","volume":"142","author":"NA Schubert","year":"2020","unstructured":"Schubert, N. A. et al. Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. Eur. J. Cancer 142, 1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.009 (2020).","journal-title":"Eur. J. Cancer"},{"key":"16455_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0304-3835(03)00088-0","volume":"197","author":"DA Tweddle","year":"2003","unstructured":"Tweddle, D. A. et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197, 93\u201398. https:\/\/doi.org\/10.1016\/s0304-3835(03)00088-0 (2003).","journal-title":"Cancer Lett."},{"key":"16455_CR54","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1078-0432.CCR-09-1865","volume":"16","author":"J Carr-Wilkinson","year":"2010","unstructured":"Carr-Wilkinson, J. et al. High frequency of p53\/MDM2\/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin. Cancer Res. 16, 1108\u20131118. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1865 (2010).","journal-title":"Clin. Cancer Res."},{"key":"16455_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1480290","author":"J He","year":"2018","unstructured":"He, J. et al. Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm. Cancer Biol. Ther. https:\/\/doi.org\/10.1080\/15384047.2018.1480290 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"16455_CR56","doi-asserted-by":"publisher","first-page":"27990","DOI":"10.18632\/oncotarget.15856","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu, Q. et al. Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. Oncotarget 8, 27990\u201327996. https:\/\/doi.org\/10.18632\/oncotarget.15856 (2017).","journal-title":"Oncotarget"},{"key":"16455_CR57","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537\u2013549. https:\/\/doi.org\/10.1016\/s1535-6108(03)00132-6 (2003).","journal-title":"Cancer Cell"},{"key":"16455_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3753","author":"A Furlan","year":"2017","unstructured":"Furlan, A. et al. Multipotent peripheral glial cells generate neuroendocrine cells of the adrenal medulla. Science https:\/\/doi.org\/10.1126\/science.aal3753 (2017).","journal-title":"Science"},{"key":"16455_CR59","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/s41467-021-24870-7","volume":"12","author":"OC Bedoya-Reina","year":"2021","unstructured":"Bedoya-Reina, O. C. et al. Single-nuclei transcriptomes from human adrenal gland reveal distinct cellular identities of low and high-risk neuroblastoma tumors. Nat. Commun. 12, 5309. https:\/\/doi.org\/10.1038\/s41467-021-24870-7 (2021).","journal-title":"Nat. Commun."},{"key":"16455_CR60","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ccell.2020.08.014","volume":"38","author":"R Dong","year":"2020","unstructured":"Dong, R. et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell 38, 716-733 e716. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.014 (2020).","journal-title":"Cancer Cell"},{"key":"16455_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022350118","author":"ES Hanemaaijer","year":"2021","unstructured":"Hanemaaijer, E. S. et al. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype. Proc. Natl. Acad. Sci. U. S. A. https:\/\/doi.org\/10.1073\/pnas.2022350118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"16455_CR62","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41588-021-00806-1","volume":"53","author":"S Jansky","year":"2021","unstructured":"Jansky, S. et al. Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma. Nat. Genet. 53, 683\u2013693. https:\/\/doi.org\/10.1038\/s41588-021-00806-1 (2021).","journal-title":"Nat. Genet."},{"key":"16455_CR63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41588-021-00818-x","volume":"53","author":"P Kameneva","year":"2021","unstructured":"Kameneva, P. et al. Single-cell transcriptomics of human embryos identifies multiple sympathoblast lineages with potential implications for neuroblastoma origin. Nat. Genet. 53, 694\u2013706. https:\/\/doi.org\/10.1038\/s41588-021-00818-x (2021).","journal-title":"Nat. Genet."},{"key":"16455_CR64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y","volume":"86","author":"H Shimada","year":"1999","unstructured":"Shimada, H. et al. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 86, 349\u2013363 (1999).","journal-title":"Cancer"},{"key":"16455_CR65","doi-asserted-by":"publisher","first-page":"22432","DOI":"10.1038\/s41598-020-78370-7","volume":"10","author":"S Fransson","year":"2020","unstructured":"Fransson, S. et al. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance. Sci. Rep. 10, 22432. https:\/\/doi.org\/10.1038\/s41598-020-78370-7 (2020).","journal-title":"Sci. Rep."},{"key":"16455_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326. https:\/\/doi.org\/10.1038\/nbt.1754 (2011).","journal-title":"Nat. Biotechnol."},{"key":"16455_CR67","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."},{"key":"16455_CR68","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3892\/ijo.2011.1120","volume":"39","author":"H Kryh","year":"2011","unstructured":"Kryh, H. et al. MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. Int. J. Oncol. 39, 1063\u20131071. https:\/\/doi.org\/10.3892\/ijo.2011.1120 (2011).","journal-title":"Int. J. Oncol."},{"key":"16455_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7550","author":"G Umapathy","year":"2017","unstructured":"Umapathy, G. et al. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.aam7550 (2017).","journal-title":"Sci. Signal."},{"key":"16455_CR70","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: A web application for analyzing drug combination dose-response matrix data. Bioinformatics 33, 2413\u20132415. https:\/\/doi.org\/10.1093\/bioinformatics\/btx162 (2017).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16455-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16455-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:27:24Z","timestamp":1669350444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16455-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16455"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16455-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"20 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12420"}}